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Abstract
We studied in vivo the potential involvement of nuclear factor-jB (NF-jB)
pathway in the molecular mechanism of the anti-inflammatory and immuno-
modulatory activity of azithromycin in the lung. Mice transiently transfected
with the luciferase gene under the control of a NF-jB responsive element were
used to assess in vivo NF-jB activation by bioluminescence imaging. Biolumi-
nescence as well as inflammatory cells and concentrations of proinflammatory
cytokines in bronchoalveolar lavage fluids, were monitored in an acute model
of pulmonary inflammation resulting from intratracheal instillation of lipopoly-
saccharide. Lipopolysaccharide (LPS) instillation induced a marked increase in
lung bioluminescence in mice transiently transfected with the luciferase gene
under the control of an NF-jB responsive element, with significant luciferase
expression in resident cells such as endothelial and epithelial cells, as assessed
by duoplex immunofluorescence staining. Activation of NF-jB and inflamma-
tory cell lung infiltration linearly correlated when different doses of bortezomib
were used to inhibit NF-jB activation. Pretreatment with azithromycin signifi-
cantly decreased lung bioluminescence and airways cell infiltration induced by
LPS, also reducing proinflammatory cytokines concentrations in bronchoalveo-
lar lavages and inhibiting NF-jB nuclear translocation. The results obtained
using a novel approach to monitor NF-jB activation, provided, for the first
time, in vivo evidence that azithromycin treatment results in pulmonary anti-
inflammatory activity associated with the inhibition of NF-jB activation in the
lung.
Introduction
Macrolide antibiotics were shown to have immunomodula-
tory and anti-inflammatory, as well as antibacterial effects
(Culic et al. 2001; Martinez et al. 2008; Kanoh and Rubin
2010). In vitro azithromycin inhibits the release of the neu-
trophil chemoattractant interleukin(IL)-8 and of granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) by
lipopolysaccharide (LPS)-activated, human primary bron-
chial epithelial cells (Murphy et al. 2008), and in vivo
azithromycin has been shown to inhibit LPS-induced
mouse pulmonary neutrophilia (Bosnar et al. 2009). In
potential agreement with these activities, azithromycin
significantly decreased the rate of exacerbation in chronic
obstructive pulmonary disease (COPD) patients (Albert
et al. 2011) as well as in non-cystic fibrosis bronchiectasis
patients (Wong et al. 2012), but the molecular mechanism
of its pulmonary anti-inflammatory activity has not yet
been elucidated.
Airway infiltration by polymorphonuclear leukocytes
(PMNs) in response to bacterial and viral infections repre-
sents a pivotal feature of lung inflammatory reactions and
is both directly and indirectly involved in most lung
pathologies (Murugan and Peck 2009). Mobilization of
PMNs to inflamed lungs is modulated by a complex inter-
play between cytokines, endothelial cells, and neutrophils.
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During the acute-phase response to infectious agents in
ruminants and humans, inflammatory cytokines such as
IL-1b, tumor necrosis factor(TNF)-a and IL-8, secreted by
a variety of immune and nonimmune cell types, induce a
strong PMNs infiltration that sometimes fail to control
the infection, and may even contribute to the development
of lesions in the lung (Malazdrewich et al. 2001; Mukaida
2003; Murugan and Peck 2009).
Since its discovery in 1986 (Sen and Baltimore 1986),
the role of ubiquitous nuclear factor-jB (NF-jB) tran-
scription factor has been extensively studied in tumori-
genesis, immunity, and inflammatory responses, and its
dysregulated activation has been associated with malig-
nancies as well as to inflammatory pathological conditions
(Bours et al. 2000; Salminen et al. 2008; Tornatore et al.
2012).
In the lungs, several noxious/inflammatory stimuli
activate NF-jB, including intact bacteria, Gram-negative
bacterial LPS, ozone, and silica delivered directly to the
airways, as well as systemic inflammatory insults such as
sepsis, hemorrhage, and direct liver injury (Blackwell
et al. 1994, 2000). In rodent models of lung inflammation
induced by LPS, pretreatment with relatively nonspecific
inhibitors of NF-jB activation was found to decrease lung
inflammation (Lauzurica et al. 1999), and mice deficient
in both RelA (the transactivating subunit of NF-jB) and
type 1 TNF receptor (TNFR1) showed impaired neutro-
phil recruitment to the lungs in response to LPS (Alcamo
et al. 2001).
To dynamically investigate in vivo, the involvement of
NF-jB in the inflammatory response, a transgenic mouse
model was developed expressing the minimal promoter of
NF-jB and the luciferase gene as a reporter, allowing a
direct monitoring of NF-jB activation by bioluminescence
(Carlsen et al. 2002; Everhart et al. 2006; Kielland and
Carlsen 2010). BLI is based on the detection of light emis-
sion from cells or tissues (Doyle et al. 2004), and requires
an expression cassette consisting of the bioluminescence
reporter gene (in this case was luciferase) under the con-
trol of a selected promoter (in this experimental setting
the NF-jB gene promoter) driving the reporter. To induce
light production, the substrate luciferin must be provided
by intravascular or intraperitoneal injection immediately
prior to bioluminescence imaging (BLI) evaluation. BLI
has proven to be a very powerful technique, facilitating
real-time, molecular level analysis of disease progression.
Nevertheless the generation, characterization, and colony
management of transgenic mice may be difficult, and typi-
cally very expensive. An alternative, relatively inexpensive
approach is represented by the use of transient transgenic
mice obtained through the infusion of a polyethylenimine
(PEI)/DNA complex containing plasmids with specific
responsive elements and luciferase as a reporter gene. This
technique yields significant transfection in vivo, as was
recently shown by imaging pulmonary NF-jB activation
in LPS-treated mice (Ansaldi et al. 2011).
In this work, we studied the correlation between lung
bioluminescence and lung inflammatory cell infiltration
in mice transiently transfected with the luciferase (luc)
gene under the control of an NF-jB responsive element,
upon intratracheal challenge with LPS, and we took
advantage of this unique model to provide novel, in vivo
evidence that the molecular mechanism of action of the
anti-inflammatory activity of the macrolide antibiotic
azithromycin involves the modulation of NF-jB activa-
tion in lung resident cells.
Materials and Methods
Animals
Female FVB (7–8 week-old) mice were purchased from
Harlan Laboratories Italy (S. Pietro al Natisone, Udine,
Italy). Animals were maintained under conventional
housing conditions. Prior to use, animals were acclimated
for at least 5 days to the local vivarium conditions (room
temperature: 20–24°C; relative humidity: 40–70%), having
free access to standard rat chow and tap water. All animal
experiments were carried out in agreement with the
revised “Guide for the Care and Use of Laboratory
Animals” (1996) and were approved by the Institutional
Animal Care and Use Committee at Chiesi Farmaceutici.
The study adhered to the ARRIVE guidelines (McGrath
et al. 2010).
Reagents
LPS (from Escherichia coli 0111:B4, product n.L3012) was
from Sigma (St. Louis, MO); azithromycin (Zitromax) was
from Pfizer Inc (Latina, Italy); JetPEI was from Polyplus-
transfection Inc (Euroclone, Milano, Italy); NF-jB vector
(pGL4.32[luc2P/NF-jB-RE/Hygro]) was from Promega
(Madison, WI); bortezomib (Velcade) was from Millen-
nium Pharmaceuticals (Cambridge, MA).
Vector characteristic and in vivo gene
delivery
The pGL4.32[luc2P/NF-jB-RE/Hygro] vector (GenBank/
EMBL Accession Number EU581860) contains five copies
of an NF-jB responsive element (NF-jB-RE) that drives
transcription of the luciferase reporter gene luc2P (Photi-
nus pyralis). Luc2P is a synthetically derived luciferase
sequence with humanized codon optimization that is
designed for high expression and reduced anomalous
transcription.
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The luc2P gene contains hPEST, a protein destabiliza-
tion sequence. The protein encoded by luc2P responds
more quickly than the protein encoded by the luc2 gene
upon induction. The vector backbone contains a resis-
tance gene to allow selection in E. coli and a mammalian
selectable marker for hygromycin resistance.
JetPEI (Wu et al. 2004; Oh et al. 2013) was applied in
vivo as a carrier for delivering DNA to lung tissues. The
DNA and JetPEI were formulated according to the prod-
uct manual. Briefly, 40 lg of NF-jB-luc reporter and
7 lL of JetPEI were each diluted into 100 lL 5% glucose.
The two solutions were then mixed and incubated for
15 min at room temperature.
The entire mixture (app.ly 200 lL) was injected into
the tail vein of mice.
In vivo bioluminescence imaging
Transfection per se causes a mild lung inflammatory response
and NF-jB activation that is detectable by BLI up to 3–
4 days after DNA injection and disappears completely after
1 week. Therefore 1 week after DNA delivery, the transient
transgenic mice were injected with luciferin i.p. and BLI was
recorded to check the baseline activation of the NF-jB path-
way. Briefly, following intraperitoneal injection of luciferin
(150 mg/kg) mice were lightly anesthetized with isoflurane
(2.5%) and images were obtained using an IVIS imaging sys-
tem (Caliper Life Sciences, Alameda, CA) at 10 and 15 min
after luciferin: an average of photons emitted from the chest
of the mice was quantified using Living Image software
(Caliper Life Sciences). The following day, mice were intrat-
racheally challenged with LPS (12.5 lg/mouse) and BLI was
recorded at 2, 4, 7, and 24 h after LPS instillation, 15 min
after i.p. injection of luciferin (150 mg/kg).
Immunofluorescence staining of luciferase,
CD31 and cytokeratin 18 (CK18)
To identify the type of cell expressing luciferase protein,
duoplex immunofluorescence staining was performed with
anti-luciferase antibody and either an anti-CD31 (an endo-
thelial cell marker) or anti-CK18 (an epithelial cell marker).
Briefly, during necropsy, 4% paraformaldehyde was first
injected through the right ventricle/pulmonary artery to
inflate the blood vessel within the lung tissue, and subse-
quently injected through the trachea to inflate the alveoli.
Lung samples were then embedded in paraffin and cut into
5-lm sections, deparaffinized, microwaved in Citra Plus
(pH 6; BioGenex, Fremont, CA) for antigen retrieval, and
blocked with Antibody Diluent (Dako, Carpintiria, CA).
Sections were then incubated with anti-luciferase antibody
(Novus Biologicals, Littleton, CO) at 1:100 dilution and 4°C
overnight, followed by anti-goat secondary antibody
conjugated with Alexa Fluor 594 (Invitrogen, Grans Island,
NY) for 1 h. Thereafter, sections were incubated with anti-
CD31 antibody (Abcam, Cambridge, MA) at 1:100 dilution
for 1 h, followed by anti-mouse secondary antibody conju-
gated with Alexa Fluor 488 for 1 h, and finally by 40,6-dia-
midino-2-phenylindole (DAPI) for 5 min for nuclear
staining. For Luciferase/CK18 duoplex staining, after depa-
raffinization, microwaving and blocking, sections were incu-
bated with an anti-CK18 antibody (Abcam) at 1:500
dilution for 1 h, followed by SuperPicture horseradish
peroxidase-conjugated anti-mouse secondary antibody
(Invitrogen) for 5 min, and tyramide signal amplification
conjugated fluorescein (PerkinElmer, Alameda, CA) for
10 min. Thereafter, sections were microwaved again,
blocked and then incubated with anti-luciferase antibody at
1:100 overnight, followed by anti-goat secondary antibody
conjugated with Alexa Fluor 594 for 1 h, and DAPI for
5 min for nuclear staining. Images were captured with a
Vectra-2 Imaging System (PerkinElmer).
Acute pulmonary inflammation: effect
of bortezomib and azithromycin
Intratracheal (i.tr.) challenge with LPS was carried out
using 50 lL of LPS solution (250 lg/mL in phosphate buf-
fered solution [PBS]) and a 22-gauge intubator, resulting
in a final dose of LPS of 12.5 lg/mouse, with the control
group receiving 50 lL of saline i.tr.. In a limited number
of mice, 4 h after LPS challenge and luciferin administra-
tion, lungs were rapidly excised and BLI recorded at 10
and 15 min after luciferin, as described for intact animals.
Bortezomib was administered by injection into the tail
vein at different doses (0.5–1 mg/kg, Psallidas et al. 2010)
1 h before LPS i.tr. instillation.
Azithromycin (Zitromax solution) was administered
p.o. by gavage at different doses (100–600 mg/kg) (Bosnar
et al. 2009) 4 h before LPS i.tr. instillation.
Bronchoalveolar lavage and cytokine
determination
Twenty-four hours after LPS challenge, animals were
weighted, anaesthetized with isoflurane and sacrificed by
bleeding from the abdominal aorta for bronchoalveolar
lavage fluid (BALF) collection, performed as previously
described (Nassini et al. 2012). Bronchoalveolar lavage
(BAL) fluid supernatants were frozen at 80°C for simul-
taneous quantitation of multiple cytokines/chemokines
using a Bio-PlexTM Cytokine Assay Kit (Bio-Rad Laborato-
ries, Segrate, Milano, Italy).
The cell pellet was resuspended in 0.2 mL of PBS and
cell counts were obtained using a particle counter (Dasit
XT 1800J, Cornaredo, Milano, Italy).
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p65 nuclear translocation
Lungs were excised and homogenized using a trans
Turrax homogenizer. Cytoplasmatic and nuclear extracts
were obtained using Nuclear Extraction Kit (Active Motif,
La Hulpe, Belgium), and determination of p65 was car-
ried out using TransAM NFkB p65 transcription factor
assay kit (Active Motif), according to the manufacturer
instructions.
Data analysis
As tests for normality were positive, statistical analysis
was performed on raw data using one-way analysis of var-
iance (ANOVA) followed by Dunnett’s t post-hoc test for
comparison with control groups. Experimental values
were expressed as the mean and standard error of the
mean (SEM) of n observations. (*P < 0.05, **P < 0.01).
Results
As previously reported, LPS intratracheal instillation 1 week
after DNA delivery of the luciferase reporter construct
caused activation of NF-jB that could be easily monitored
by BLI, showing a very marked increase when compared to
control animals (Fig. 1A). Ex-vivo imaging of isolated lungs
confirmed that the bioluminescence observed in vivo was
associated to the activation of NF-jB in the lungs (Fig. 1B).
Luc expression driven by NF-jB activation was detectable
by BLI as early as 2 h after LPS challenge, peaked at 4 h
after treatment, with a 10-fold induction over baseline. This
signal was still significantly enhanced 7 h after LPS, but
returned to baseline levels 24 h after LPS challenge
(Fig. 1C). Double staining immunofluorescence analysis
performed to identify which cell type(s) is(are) targeted by
the injected plasmid DNA showed LPS-induced expression
of luciferase in both epithelial (Fig. 2A–D) or endothelial
(Fig. 2E–H) cells. While regular staining was observed for
CK18 and CD31 (Fig. 2I and K, and Fig. S1A and C), no
signal for luciferase was observed in LPS-challenged wild
type animals (Fig. 2J) or in saline-challenged NF-jB-luc
animals (Fig. S1B and D).
Bortezomib (Velcade), a known proteasome inhibitor
that interferes with the degradation of IkB and therefore
the activation of NF-jB, dose dependently inhibited lucif-
erase expression 4 h after LPS administration (Fig. 3A
and B), lending support to the quantitative correlation
between NF-jB activation and bioluminescence determi-
nation in the transient transgenic mice. In agreement with
the fact that the expression of adhesion molecules leading
to white blood cells (WBC) extravasation and infiltration
are results of NF-jB activation (Read et al. 1995; Kalogeris
et al. 1999; Dagia and Goetz 2003), increased numbers of
WBC and neutrophils were also recovered by BAL 24 h
after LPS challenge (Fig. 4A and B) and this increase was
also significantly inhibited by bortezomib treatment. A
strong correlation was observed between bioluminescence
observed 4 h after LPS administration and the number of
WBC and neutrophils recovered by BAL 24 h after LPS
challenge (Fig. 4C), further supporting the ability of this
transient transgenic mouse model to provide an accurate,
in vivo determination of NF-jB activation in the lung.
Pre-treatment of transient transgenic mice with azithro-
mycin per os, dose-dependently inhibited bioluminescence
induced by LPS tracheal instillation (9.5  1.74 fold,
6.9  1.82 and 4.16  0.78 fold of induction over baseline
at 4 h in LPS-control, azithromycin 100 mg/Kg p.o., and
azithromycin 600 mg/Kg p.o., respectively) (Fig. 5A and
(A) (C)
(B)
Figure 1. (A) In vivo imaging of NF-jB activation 4 h after LPS challenge. LPS (12.5 lg/mouse) was administered intratracheally. Representative
mice are shown for saline and LPS groups. (B) Ex vivo imaging of NF-jB activation in lungs excised 4 h after LPS treatment. Representative lungs
are shown for saline and LPS groups. (C) Time-course of luciferase induction in mice challenged with intratracheal LPS. Values are shown as
mean  SEM, n = 12 at each time point P < 0.05, **P < 0.01 versus saline group (Dunnett’s t test).
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B). As observed with bortezomib, the inhibition of BLI was
followed by a significant inhibition of WBC and neutrophil
infiltration at 24 h confirming the anti-inflammatory
activity of this compound (Fig. 6A and B).
The inhibitory activity of azithromycin on NF-jB acti-
vation, also resulted in a statistically significant inhibition
in the BAL concentrations of several pro-inflammatory
cytokines, such as TNF-a, granulocyte colony-stimulating
(A) (B) (C) (D)
(F) (G) (H)(E)
(J) (K)(I)
Figure 2. Double immunofluorescence staining of mice lungs. Duoplex immunofluorescence staining of luciferase/CK18 (epithelial cell marker) or
luciferase/CD31(endothelial cell marker) were performed on paraformaldehyde-fixed lung sections, as described in Materials and Methods. Double
staining showed that in LPS-challenged NF-kB-luc mice both epithelial cells (A) and endothelial cells (E) were expressing luciferase (B and F), and
displayed yellow immunofluorescence when the two images were merged (C and G, respectively); larger magnifications of the merged images are
reported in (D and H). Immunofluorescence staining of CK18 (I), luciferase (J) and CD31 (K) in LPS-challenged wild type mice, confirmed the
absence of signal for luciferase. Original magnification: (A–C, E–G, and J) 210X; (D, H, I, and K) 600X.
(A) (B) (E)
(C) (D)
Figure 3. (A–D) In vivo imaging of NF-jB activation 4 h after LPS treatment: effects of pretreatment with bortezomib. Transient NF-jB-luc
transgenic mice were pretreated with saline or bortezomib (BZM, 0.5–1 mg/kg) i.v. 1 h before LPS intratracheal instillation. Representative mice
are shown for saline (A), LPS (B), LPS+BZM 0.5 mg/kg (C) and LPS+BZM 1 mg/kg (D and E). Quantification of NF-jB activation by BLI, 4 h after
LPS intratracheal instillation. Values are shown as mean  SEM, n = 8 for each group, and% inhibition versus LPS group is reported. **P < 0.01
versus LPS group (Dunnett’s t test)
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factor (G-CSF) and monocyte chemoattractant protein-1
(MCP-1) (Fig. 7A–F), while other cytokines upregulated
by LPS were not affected (Fig. S2A–E). A complete list of
cytokines analyzed is reported in Table 1S.
Time-course of p65 nuclear translocation paralleled luc
signal induction, with maximal accumulation occurring at
4 h, while by 24 h p65 was again localized primarily in
cytoplasm (data not shown); azithromycin treatment
inhibited by 52% (P < 0.05) the nuclear translocation of
activated NF-jB observed in lung homogenates 4 h after
LPS tracheal instillation.
Discussion
The results obtained provided, for the first time, in vivo
evidence that azithromycin treatment results in pulmo-
nary anti-inflammatory activity associated with the inhibi-
tion of NF-jB activation in the lung, as followed by
bioluminescence monitoring in mice transiently transfect-
ed with luciferase gene under the control of an NF-jB
responsive element (Ansaldi et al. 2011).
While a limited number of evidence obtained in vitro
using different cell types, including airways cells, pointed
to the inhibition of NF-jB as part of the mechanism of
the anti-inflammatory activity of azithromycin (Aghai
et al. 2007; Cigana et al. 2007; Matsumura et al. 2011;
Vrancic et al. 2012), the only evidence available in vivo
was obtained in a model of ocular inflammation, where it
was shown that azithromycin treatment decreased the
amount of NF-jB protein detected by western blot in
conjunctival homogenates, a measurement that does not
actually evaluate changes in NF-jB activation. On the
other side, studying the activity of azithromycin in a
model of LPS-induced pulmonary neutrophilia Boznar
and co. could not show any inhibitory effect on NF-jB
activation in alveolar macrophages (Bosnar et al. 2011).
The ability, offered by the animal model used in this
study, to evaluate and monitor NF-jB activation in
vivo at the whole organ level, clearly showed that a signif-
icant activation of NF-jB is indeed taking place in the
lung upon intratracheal LPS challenge, and that azithro-
mycin anti-inflammatory activity significantly inhibited
(A) (B)
(C)
Figure 4. (A and B) LPS-induced neutrophil and white blood cells (WBC) recruitment in the airways: effects of bortezomib. Transient NF-jB-
luc transgenic mice were pretreated with saline or bortezomib (BZM, 0.5–1 mg/kg, i.v.) 1 h before LPS, and sacrificed 24 h after LPS
administration by tracheal instillation. Values are shown as mean  SEM, n = 8 for each group, and% inhibition versus LPS group is reported.
**P < 0.01 versus LPS group (Dunnett’s test, C). Correlation between NF-jB activation as measured by BLI, 4 h after LPS instillation, and the
concentration of WBC in BAL lavage fluids, obtained 24 h after LPS instillation, in saline, LPS, LPS+BZM 0.5 mg/kg and LPS+BZM 1 mg/kg
groups.
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NF-jB activation-dependent bioluminescence. Luciferase
co-expression with epithelial and endothelial cell-specific
markers, as assessed by duoplex immunofluorescence,
suggests that these cells may therefore represent potential
targets of the activity of azithromycin. It must be noted
that although cytokeratins are considered a typical marker
of epithelial differentiation, they can also be expressed in
certain vascular smooth muscle cells (Bar et al. 2001).
Although no infiltrating inflammatory cells showed up
significantly expressing luciferase, this does not rule out
the activation of NF-jB in neutrophils, as their rapid turn-
over likely prevents them from being detected at the time-
points used for LPS challenge after transient transfection.
NF-jB activation upon LPS challenge resulted in a
rather striking correlation between bioluminescence
induced by NF-jB activation and inflammatory biomar-
kers such as WBC and neutrophils airways infiltration, as
shown by the parallelism between changes in these
parameters induced by LPS alone or in the presence of
increasing doses of a potent proteasome inhibitor (bort-
ezomib) known to inhibit NF-jB activation, by blocking
the degradation of IjB, the inhibitory unit of the NF-jB
complex, carried out by the 26S proteasome.
Dysregulation of NF-jB activation has been involved in
lung diseases such as asthma, chronic bronchitis, and
COPD (Donovan et al. 1999; Teramoto and Kume 2001),
but its specific contribution to disease progression is cur-
rently unknown (Lawrence et al. 2001). BLI provides a
noninvasive approach to monitor gene expression in vivo
and represent an important tool to evaluate the potential
contribution of NF-jB to the evolution of acute inflam-
matory reactions.
BLI is a powerful technique based on the detection of
visible light produced during luciferase-mediated oxidation
of a molecular substrate in the presence of the enzyme
resulting from its expression in vivo as a molecular repor-
ter. Bioluminescence arising from luciferase can be imaged
as deep as several centimeters within tissues, allowing at
least organ-level resolution. Being simple to execute and
minimally invasive, BLI enables monitoring and serial
quantification of biological processes without sacrificing
the experimental animal. This powerful technique can
(A) (B)
(D)(C)
Figure 5. (A and B) In vivo imaging of NF-jB activation 4 h after LPS treatment: effect of azithromycin. Transient NF-jB-luc transgenic mice were
pretreated with saline or azithromycin (100–600 mg/Kg, per os) 4 h before LPS intratracheal instillation. Representative mice are shown for saline
(A), LPS (B), LPS+AZI 100 mg/kg (C) and LPS+AZI 600 mg/kg (D).
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therefore reduce the number of animals required for
experimentation because multiple measurements can be
made in the same animal over time, also minimizing the
effects of biological variation.
In this study, we confirm the activity of azithromycin
against pulmonary inflammation induced by LPS (Ianaro
et al. 2000), showing a reduction in WBC and neutrophil
airways infiltration and a significant decrease in the con-
centrations of proinflammatory cytokines in BAL. It must
be noted that in this study azithromycin has been used
prophylactically to prevent an acute inflammatory response
mainly because we have been trying to establish a link
between its anti-inflammatory activity and NF-jB activa-
tion in vivo. Indeed, taking advantage of BLI on transiently
transfected animals, we provide unequivocal evidence that
this activity is associated with a significant inhibition of
NF-jB activation in vivo. Double immunofluorescence
staining with antibodies targeting luciferase protein and
specific cell type antigens, showed that in transient NF-jB-
luc transgenic mice intratracheal challenge with LPS
induces luciferase expression both in epithelial and endo-
thelial cells, suggesting a key role for these cell types in the
inflammatory response to bacterial infection. Although no
infiltrating inflammatory cells resulted in expressing lucifer-
ase, this does not rule out the activation of NF-jB in these
cells, but it rather reflects their rapid turnover.
This innovative analytical approach to the in vivo mon-
itoring of pulmonary inflammation through the analysis
of bioluminescence in transiently transfected mice, can
certainly be used to test different macrolide antibiotics for
their effects on NF-jB activation, or, taking advantage of
different vectors, to monitor different models of pathol-
ogy (fibrosis, asthma etc.).
As previously reported, azithromycin was also able to
significantly reduce the concentrations of G-CSF within
the airways, and this activity may result in a decrease in
epithelial cells-dependent neutrophil survival within the
airways (Yamasawa et al. 2004), and contribute to the
reported effects, among others, on COPD exacerbations
(Albert et al. 2011; Yamaya et al. 2012).
(A) (B)
(C)
Figure 6. (A and B) LPS-induced WBC (A) and neutrophil (B) recruitment in the airways: effect of azithromycin. Transient NF-jB-luc transgenic
mice were pretreated with saline or Azithromycin (AZI, 100–600 mg/kg, per os) 4 h prior to LPS, and sacrificed 24 h after LPS administration by
tracheal instillation. (C) Quantitation of NF-jB activation by BLI, 4 h after LPS intratracheal instillation: effect of azithromycin. Values are shown as
mean  SEM, n = 8 for each group and% inhibition versus LPS group is reported. P < 0.05, **P < 0.01 versus LPS group (Dunnett’s t test).
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Not much is known on the molecular mechanism of
the inhibition of NF-jB by azithomycin, but the possibil-
ity that the anti-inflammatory activity of macrolide anti-
biotics such as azythromycin or erythromycin may relate
uniquely to their antibiotic activity has been ruled out by
the identification of an erythromycin analog devoid of
the antibiotic activity but retaining the anti-inflammatory
action (Desaki et al. 2004). Conversely, it has been shown
that azithromycin inhibits the binding of activator pro-
tein-1, nuclear factor of activated T cells, and interferon
consensus sequence binding protein to the DNA-binding
site in the IL-12p40 promoter (Yamauchi et al. 2009),
and down regulation of TLR-4 receptor by azithromycin
has also been reported (Iwamoto et al. 2011), and these
could represent important mechanisms contributing to
the anti-inflammatory effects of azithromycin.
In consideration of the striking correlation of NF-jB
activation as assessed by BLI, and downstream airway
inflammatory responses, monitoring of BLI in this rela-
tively simple model of transient transgenic mouse may
represent a suitable approach for in vivo assessment
of NF-jB-associated inflammatory responses, and pos-
sess significant potential for the elucidation of molecular
mechanisms in the pathobiology of lung diseases.
In conclusion, taking advantage of a transient trans-
genic mice expressing luciferase under the control of
NF-jB-responsive elements, we provide evidence that
azithromycin inhibits NF-jB activation in vivo, further
supporting the important contribution of this mechanism
of action to its anti-inflammatory activity.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Double immunofluorescence staining of mice
lungs. Duoplex immunofluorescence staining of luciferase/
CK18 (epithelial cell marker) or luciferase/CD31(endothelial
cell marker) were performed on paraformaldehyde-fixed
lung sections, as described in Materials and Methods.
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Double staining of lung obtained from saline-challenged
NF- jB-luc mice showed normal staining of epithelial cells
(A) and endothelial cells (C) for CK18 and CD31, respec-
tively. On the contrary, no staining for luciferase was
observed (B and D). Original magnification: 2109.
Figure S2. (A–E). LPS-induced cytokines in bronchoalveo-
lar lavage fluid (BALF): effect of azithromycin. Transient
NF-jB-luc transgenic mice were pretreated with saline or
azithromycin (AZI, 100–600 mg/kg, per os) 4 h prior to
LPS and sacrificed 24 h after tracheal instillation of LPS. A:
IL1-a. B: IL1-b. C: IL-12. D: IL-12(p70). E: KC. Values are
shown as mean  SEM, n = 6 for each group.
Table S1. Cytokines analyred in BAL of LPS-challenged
mice. Cytokines modulated by LPS showed a statistically
significant increase in BAL concentrations obtained after
LPS challenge.
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